Latest News for: amph
Edit
Why Amphastar Pharmaceuticals (AMPH) Stock Is Nosediving
The Call 15 Jan 2026
What Happened? ... The analyst trimmed the price target to $30 from $31 while keeping a Neutral rating ... For instance, iron sucrose sales were forecasted at around $5 million per quarter, and glucagon sales were anticipated to trend down ... More News ... .
Edit
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today
The Call 12 Jan 2026
What Happened? ... for a new drug compound. The deal was for the development and commercialization of AMP-110, a fully synthetic human hormone analog, in the United States and Canada ... The shares closed the day at $29.41, up 6% from previous close ... .
Edit
Amphastar Pharmaceuticals (AMPH) Stock Trades Up, Here Is Why
The Call 03 Dec 2025
What Happened?. Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.7% in the afternoon session after positive analyst sentiment and technical trading indicators pointed to potential upside for the stock ... More News ... Okta ... .
Edit
Why Are Amphastar Pharmaceuticals (AMPH) Shares Soaring Today
The Call 10 Nov 2025
What Happened? ... Amphastar posted revenue of $191.8 million and adjusted earnings of $0.93 per share, beating Wall Street's consensus estimates. The strong performance was reportedly driven by robust sales of its products Baqsimi and Primatene Mist ... .
Edit
AMPH Q3 Deep Dive: Pipeline Expansion and Core Product Growth Offset Margin Pressures
The Call 10 Nov 2025
Its non-GAAP profit of $0.93 per share was 12.7% above analysts’ consensus estimates. Is now the time to buy AMPH? Find out in our full research report (it’s free for active Edge members). Amphastar Pharmaceuticals (AMPH) Q3 CY2025 Highlights.. Revenue.
- 1